The observation that IGFBP3 levels are increased in patients with T1D or T2D and in those at risk for developing diabetes, as well as in pre-diabetic and diabetic mice, suggests a dysregulation of the IGFBP3/TMEM219 pathway in the context of diabetes. The gene discussed is IGFBP3; the disease is diabetes mellitus.